» Articles » PMID: 23384790

Nanoparticle Diffusion in Respiratory Mucus from Humans Without Lung Disease

Overview
Journal Biomaterials
Date 2013 Feb 7
PMID 23384790
Citations 138
Authors
Affiliations
Soon will be listed here.
Abstract

A major role of respiratory mucus is to trap inhaled particles, including pathogens and environmental particulates, to limit body exposure. Despite the tremendous health implications, how particle size and surface chemistry affect mobility in respiratory mucus from humans without lung disease is not known. We prepared polymeric nanoparticles densely coated with low molecular weight polyethylene glycol (PEG) to minimize muco-adhesion, and compared their transport to that of uncoated particles in human respiratory mucus, which we collected from the endotracheal tubes of surgical patients with no respiratory comorbidities. We found that 100 and 200 nm diameter PEG-coated particles rapidly penetrated respiratory mucus, at rates exceeding their uncoated counterparts by approximately 15- and 35-fold, respectively. In contrast, PEG-coated particles ≥500 nm in diameter were sterically immobilized by the mucus mesh. Thus, even though respiratory mucus is a viscoelastic solid at the macroscopic level (as measured using a bulk rheometer), nanoparticles that are sufficiently small and muco-inert can penetrate the mucus as if it were primarily a viscous liquid. These findings help elucidate the barrier properties of respiratory mucus and provide design criteria for therapeutic nanoparticles capable of penetrating mucus to approach the underlying airway epithelium.

Citing Articles

Engineering Genome-Free Bacterial Cells for Effective SARS-COV-2 Neutralisation.

Yin Y, Liu C, Ji X, Wang Y, Mongkolsapaya J, Screaton G Microb Biotechnol. 2025; 18(3):e70109.

PMID: 40042439 PMC: 11881285. DOI: 10.1111/1751-7915.70109.


High-throughput Mucus Microrheology for Phenotyping and Disease Modeling.

Ling F, Sahin A, Naranjo B, Aime S, Roth D, Tepho N bioRxiv. 2025; .

PMID: 39868248 PMC: 11761623. DOI: 10.1101/2025.01.09.632077.


Pulmonary Delivery of Nonviral Nucleic Acid-Based Vaccines With Spotlight on Gold Nanoparticles.

Araujo Cirne C, Foldvari M Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025; 17(1):e70000.

PMID: 39800783 PMC: 11725562. DOI: 10.1002/wnan.70000.


Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.

Fernandez-Garcia R, Fraguas-Sanchez A Pharmaceutics. 2025; 16(12.

PMID: 39771562 PMC: 11677881. DOI: 10.3390/pharmaceutics16121584.


Breath and Beyond: Advances in Nanomedicine for Oral and Intranasal Aerosol Drug Delivery.

Du S, Wen Z, Yu J, Meng Y, Liu Y, Xia X Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770584 PMC: 11677467. DOI: 10.3390/ph17121742.


References
1.
Lai S, Wang Y, Hanes J . Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009; 61(2):158-71. PMC: 2667119. DOI: 10.1016/j.addr.2008.11.002. View

2.
Innes A, Carrington S, Thornton D, Kirkham S, Rousseau K, Dougherty R . Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am J Respir Crit Care Med. 2009; 180(3):203-10. PMC: 2724713. DOI: 10.1164/rccm.200807-1056OC. View

3.
Ensign L, Tang B, Wang Y, Tse T, Hoen T, Cone R . Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012; 4(138):138ra79. PMC: 3817739. DOI: 10.1126/scitranslmed.3003453. View

4.
Ballester M, Nembrini C, Dhar N, de Titta A, De Piano C, Pasquier M . Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine. 2011; 29(40):6959-66. DOI: 10.1016/j.vaccine.2011.07.039. View

5.
Rubin B, Ramirez O, Zayas J, Finegan B, King M . Collection and analysis of respiratory mucus from subjects without lung disease. Am Rev Respir Dis. 1990; 141(4 Pt 1):1040-3. DOI: 10.1164/ajrccm/141.4_Pt_1.1040. View